Chapter 3 Market and Technology Background
- Disease Overview
- HIV
- HIV Timeline and Milestones
- HIV Life Cycle: Treatment and Mechanism of Action
- HIV Prophylaxis
- Epidemiology
- Chlamydia
- Epidemiology
- Genital Herpes
- Epidemiology
- Gonorrhea
- Epidemiology
- Hepatitis A, B and C
- Epidemiology
- HPV
- Syphilis
- Epidemiology
- Malaria
- Incidence and Geographical Distribution
- Tuberculosis
- Incidence and Geographical Distribution
- Influenza
- Incidence and Mortality
- Trichomoniasis
- Scabies
- Bacterial Vaginosis
- Candidiasis
- Chancroid (Venereal Ulcers)
- Pediculosis Pubis
Chapter 4 Market Dynamics
- Market Drivers
- Regional Awareness Program for Communicable Diseases
- Development of Novel Therapies
- Public-Private Partnership
- Global Program to Counter HIV
- Increasing Prevalence of Communicable Diseases
- Market Restraints
- Social Stigma Associated with STD
- High Cost of Treatment
- Underestimating the Risk of Contracting the Disease
- Lack of Prenatal Screenings for STD
Chapter 5 Market Breakdown by Disease Type
- Global Market for Communicable Disease, by Disease Indication
- HIV
- Market Size and Forecast
- Market Analysis
- Hepatitis B&C
- Market Size and Forecast
- Market Analysis
- Herpes Simplex Virus
- Market Size and Forecast
- Market Analysis
- Influenza
- Market Size and Forecast
- Market Analysis
- Malaria
- Market Size and Forecast
- Market Analysis
- Tuberculosis
- Market Size and Forecast
- Market Analysis
- Others
- Market Size and Forecast
- Market Analysis
Chapter 6 Market Breakdown by Region
- Global Market for Communicable Disease, by Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Rest of Asia-Pacific
- South America
- Middle East & Africa
Chapter 7 Pipeline Analysis
- Overview
- Hepatitis B and Hepatitis C
- Herpes Simplex Virus
- HIV/AIDS
- Influenza A and Influenza B
- Respiratory Syncytial Virus
- Malaria
- Tuberculosis
- MERS
- Hemorrhagic Fevers
- Dengue
- Ebola
- Lassa fever
- Marburg
- Yellow Fever
- Zika
Chapter 8 Regulation and Reimbursement
- Regulations
- U.S.
- Europe
- Japan
- China
- Pricing and Reimbursement
- U.S.
- Europe
- Japan
Chapter 9 Competitive Landscape
- Sexually Transmitted Disease Therapeutics: Global Competitor Analysis
- Influenza Therapeutics: Global Competitor Analysis
Chapter 10 Company Profiles
- Abbott Laboratories
- Abbvie Inc.
- Astrazeneca/Medimmune
- Aurobindo Pharma Ltd.
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Bristol-Myers Squibb Co.
- Cipla Inc.
- Daiichi Sankyo
- Gilead Sciences, Inc.
- Glaxosmithkline Plc
- Janssen Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Mitsubishi Tanabe Pharma Corp.
- Mylan Laboratories
- Novartis Ag
- Pfizer Inc.
- Hoffmann-La Roche Inc.
- Sanofi, Sanofi Pasteur
- Seqirus, A Csl Company
- Viiv Healthcare
List of Tables
Summary Table: Global Communicable Disease Market, by Region, Through 2024
Table 1: Milestones in the History of HIV
Table 2: Life Cycle of HIV Therapeutics Target Points
Table 3: HIV Incidence, by Country, 2005-2016
Table 4: HIV Incidence, by Country, 2014-2017
Table 5: Chlamydia Incidence, by Country, 2012-2017
Table 6: Global HSV-1 Prevalence Aged 0-49 years, by Region, 2012
Table 7: Gonorrhea Epidemiology, by Country, 2012-2017
Table 8: Hepatitis A Incidence, by Country, 2012-2017
Table 9: Hepatitis B Incidence, by Country, 2012-2017
Table 10: Hepatitis C Incidence, by Country, 2012-2015
Table 11: Syphilis Incidence, by Country, 2013-2016
Table 12: Infectious Syphilis Incidence, by Country, 2012-2014
Table 13: Suspected Malaria Cases, by WHO Region, 2010-2015
Table 14: Confirmed Malaria Cases, by WHO Region, 2010-2015
Table 15: U.S. Impact of 2009 H1N1 Influenza, Cases and Related Hospitalizations and Deaths, by Age Group, April 2009-2010
Table 16: Trichomonas Vaginalis Diagnostic Assay, by Brand Name, Type and Manufacturer
Table 17: Bacterial Vaginosis Diagnostic Products, by Brand Name and Manufacturer
Table 18: Global Communicable Disease Market, by Disease Indication, Through 2024
Table 19: Global HIV Therapeutics Market, by Drug Class, Through 2024
Table 20: ART Therapy Coverage, by Region, 2017
Table 21: North American Estimated HBsAG Seroprevalence, 2016
Table 22: Drug for Chlamydia Treatment
Table 23: Drug for Gonorrhea Treatment
Table 24: Global Communicable Disease Market, by Region, Through 2024
Table 25: North American Communicable Disease Market, by Country, Through 2024
Table 26: European Communicable Disease Market, by Country/Region, Through 2024
Table 27: Asia-Pacific Communicable Disease Market, by Country/Region, Through 2024
Table 28: South American Estimated HBsAG Seroprevalence, by Country, 2016
Table 29: Hepatitis B and Hepatitis C Development Pipeline and Recent Launches, 2019
Table 30: Herpes Simplex Virus Development Pipeline and Recent Launches, 2019
Table 31: HIV/AIDS Development Pipeline and Recent Launches, 2019
Table 32: Influenza A and Influenza B Development Pipeline and Recent Launches, 2019
Table 33: RSV Development Pipeline and Recent Launches, 2019
Table 34: Malaria Development Pipeline and Recent Launches, 2019
Table 35: Tuberculosis Development Pipeline and Recent Launches, 2019
Table 36: MERS Development Pipeline and Recent Launches, 2019
Table 37: Dengue Development Pipeline and Recent Launches, 2019
Table 38: Ebola Development Pipeline and Recent Launches, 2019
Table 39: Lassa Fever Development Pipeline and Recent Launches, 2019
Table 40: Marburg Development Pipeline and Recent Launches, 2019
Table 41: Yellow Fever Development Pipeline and Recent Launches, 2019
Table 42: Zika Development Pipeline and Recent Launches, 2019
Table 43: Preventive Health Services for Adults Covered by Private Plans without Cost Sharing
Table 44: Preventive Health Services for Children Covered by Private Plans without Cost Sharing
Table 45: Global Market Share Analysis for Sexually Transmitted Disease Therapeutics, by Company, 2019
Table 46: Acronyms Used in This Report
List of Figures
Summary Figure: Global Communicable Disease Market Share, by Region, 2018
Figure 1: Types of Drug Failure Encountered During HIV Treatment
Figure 2: Global Historic and Current HIV Prevalence Trend, 2012-2016
Figure 3: Estimated HIV Regional Prevalence, 2016
Figure 4: Estimated HIV Regional Incidence, 2016
Figure 5: Global Historic and Current Chlamydia Incidence Women Trend, 2012-2014
Figure 6: Global Historic and Current Chlamydia Incidence Men Trend, 2012-2014
Figure 7: Global Historic and Current Gonorrhea Incidence Men Trend, 2012-2014
Figure 8: Global Historic and Current Gonorrhea Incidence Women Trend, 2012-2014
Figure 9: Hepatitis Timeline, 1990-2004
Figure 10: Hepatitis Timeline, 2011-2015
Figure 11: Hepatitis Timeline, 2015-2017
Figure 12: U.S. Syphilis Incidence Among Newborns, 2014-2016
Figure 13: Global Historic and Current Infectious Syphilis Incidence Men Trend, 2012-2014
Figure 14: Global Prevalence of Tuberculosis, 1990-2015
Figure 15: Global Incidence of Tuberculosis, 1990-2015
Figure 16: U.S. Funding Trend, HIV/AIDS, Viral Hepatitis, STIs, and TB, 2014-2017
Figure 17: Estimated Deaths Owing to Infectious and Parasitic Diseases, 2016
Figure 18: Global Historic and Current Gonorrhea Incidence Men Trend, 2012-2014
Figure 19: Global Communicable Disease Market, by Disease Indication, 2018-2024
Figure 20: Global HIV Market, 2018-2024
Figure 21: Global Prevalence of HIV, by Region, 2016
Figure 22: Global Incidence of HIV, by Region, 2016
Figure 23: Global Hepatitis Market, 2018-2024
Figure 24: Global Herpes Simplex Virus Market, 2018-2024
Figure 25: Global Market for HSV Therapeutics, by WHO Region, 2016-2022
Figure 26: Global Influenza Market, 2018-2024
Figure 27: Global Market for Influenza Therapeutics, by Contract Type, 2007-2017
Figure 28: Global Malaria Market, 2018-2024
Figure 29: Global Tuberculosis Market, 2018-2024
Figure 30: Global Others Market, 2018-2024
Figure 31: Global Communicable Disease Market Share, by Region, 2018
Figure 32: North American Communicable Disease Market, 2018-2024
Figure 33: North American Communicable Disease Market Share, by Country, 2018
Figure 34: U.S. Communicable Disease Market, 2018-2024
Figure 35: Canadian Communicable Disease Market, 2018-2024
Figure 36: Mexican Communicable Disease Market, 2018-2024
Figure 37: European Communicable Disease Market Share, by Country/Region, 2018
Figure 38: German Communicable Disease Market, 2018-2024
Figure 39: French Communicable Disease Market, 2018-2024
Figure 40: French Historic and Current Chlamydia Incidence Trend, 2011-2015
Figure 41: French Historic and Current Gonorrhea Incidence Trend, 2011-2015
Figure 42: U.K. Communicable Disease Market, 2018-2024
Figure 43: Spanish Communicable Disease Market, 2018-2024
Figure 44: Italian Communicable Disease Market, 2018-2024
Figure 45: Rest of European Communicable Disease Market, 2018-2024
Figure 46: Asia-Pacific Communicable Disease Market Share, by Country/Region, 2018
Figure 47: Japanese Communicable Disease Market, 2018-2024
Figure 48: Japanese Historic and Current HIV/AIDS Infections Incidence, 2001-2016
Figure 49: Chinese Communicable Disease Market, 2018-2024
Figure 50: Indian Communicable Disease Market, 2018-2024
Figure 51: Rest of Asia-Pacific Communicable Disease Market, 2018-2024
Figure 52: South American Communicable Disease Market, 2018-2024
Figure 53: Middle East and African Communicable Disease Market, 2018-2024
Figure 54: Global Influenza Therapeutics Market Share, by Manufacturer, 2018
Figure 55: Global Competitor Market Analysis for Influenza Therapeutics, 2018
